SEC Filing Summary: Supernus Pharmaceuticals, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Supernus Pharmaceuticals, Inc. on May 9, 2022. The filing serves to announce the Company's financial results for the first quarter ended March 31, 2022. The report incorporates a press release (Exhibit 99.1) detailing these results and references a conference call originally scheduled for March 9, 2022, to discuss business and financial performance.
Key Financial Metrics
The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The filing explicitly states that the detailed financial results are contained within the press release furnished as Exhibit 99.1, which is incorporated by reference but not reproduced in the text of this 8-K.
Material Changes
The filing text does not provide specific data regarding material changes in financial metrics compared to the prior comparable period. Investors must refer to the incorporated press release (Exhibit 99.1) for year-over-year or quarter-over-quarter comparisons.
Guidance, Outlook, and Risks
- Forward-Looking Statements: The filing contains forward-looking statements regarding plans, strategies, and intentions, identified by terms such as "believe," "expect," and "anticipate."
- Risk Factors: The Company directs readers to Item 1A, "Risk Factors," in its Annual Report on Form 10-K for the fiscal year ended December 31, 2021 (filed April 13, 2022), for a comprehensive list of risks and uncertainties.
- Legal Disclaimer: Information furnished under Item 2.02 and Item 9.01 is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not subject to the liabilities of that section.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated May 9, 2022) for specific Q1 2022 revenue, net income, and cash flow figures.
- Consult the Form 10-K filed on April 13, 2022 for detailed risk factors and audited financial statements for the prior fiscal year.
- Verify the archived webcast on the Company's website (www.supernus.com) for management commentary on the Q1 results.
- Confirm the accuracy of the conference call date referenced in the text (March 9, 2022) against the actual filing date (May 9, 2022) to ensure no discrepancies in the reporting timeline.